Subscribe to RSS
DOI: 10.1055/s-0028-1083213
Synthesis and Antiviral Evaluation of (-)-3′-Methylcarbovir, (-)-3′-Methylabacavir, and Modified Purine Analogues
Publication History
Publication Date:
30 October 2008 (online)

Abstract
Starting from ethyl (1S,4R)-4-hydroxy-2-methylcyclopent-2-ene-1-carboxylate, as a common enantiopure building block readily obtained by enzymatic kinetic resolution of the corresponding racemic derivative, 3′-methylcarbovir, 3′-methylabacavir, and three modified analogues were synthesized via the linear construction of the purine heterocycles. These derivatives were evaluated as potential agents against HIV-1, HIV-2, and other important viral pathogens. None of the new compounds had significant antiviral activity at a concentration of 100 µg˙mL-¹, which was the highest concentration tested.
Key words
stereoselective synthesis - azides - carbocyclic nucleosides - nucleobases - antiviral agents
- Supporting Information for this article is available online:
- Supporting Information
- For reviews, see:
- 1a
Huryn DM.Okabe M. Chem. Rev. 1992, 92: 1745 - 1b
Crimmins MT. Tetrahedron 1998, 54: 9229 - 1c
Ferrero M.Gotor V. Chem. Rev. 2000, 100: 4319 - 1d
Zu XF. Nucleosides, Nucleotides Nucleic Acids 2000, 19: 651 - 1e
Agrofoglio LA.Gillaizeau I.Saito Y. Chem. Rev. 2003, 103: 1875 - 1f
Rodriguez JB.Comin M. Mini-Rev. Med. Chem. 2003, 3: 95 - 2
Herdewijn P.De Clercq E.Balzarini J.Vanderhaeghe H. J. Med. Chem. 1985, 28: 550 - 3a
Bennett LL.Shannon WM.Allan PW.Arnett G. Ann. N. Y. Acad. Sci. 1975, 255: 342 - 3b
De Clercq E. J. Med. Chem. 2005, 48: 1297 - 4a
Vince R.Hua M.Brownell J.Daluge SM.Lee FC.Shannon WM.Lavelle GC.Qualls J.Weislow OS.Kiser R.Canonico PG.Schultz RH.Narayanan VL.Mayo JG.Shoemaker RH.Boyd MR. Biochem. Biophys. Res. Commun. 1988, 156: 1046 - 4b
Vince R.Hua M. J. Med. Chem. 1990, 33: 17 - 4c
Vince R. Nucleic Acids Symp. Ser. 1991, 25: 193 - 4d
Parker WB.Shaddix SC.Bowdon BJ.Rose LM.Vince R.Shannon WM.Bennett LL. Antimicrob. Agents Chemother. 1993, 37: 1004 - 5a
Daluge SM. inventors; US Patent 5034394. - 5b
Good SS.Daluge SM.Ching SV.Ayers KM.Mahony WB.Faletto MB.Domin BA.Owens BS.Dornsife RE.McDowell JA.Lafon SW.Symonds WT. Antiviral Res. 1995, 26: A229 - 5c
Crimmins MT.King BW. J. Org. Chem. 1996, 61: 4192 - 5d
Daluge SM.Good SS.Faletto MB.Miller WH.St. Clair MH.Boone LR.Tisdale M.Parry NR.Reardon JE.Dornsife RE.Averett DR.Krenitsky TA. Antimicrob. Agents Chemother. 1997, 41: 1082 - 5e
Hervey PS.Perry LM. Drugs 2000, 60: 447 - 5f
Daluge SM.Martin MT.Sickles BR.Livingston DA. Nucleosides, Nucleotides Nucleic Acids 2000, 19: 297 - 6a
Katagiri N.Nomura M.Sato H.Kaneko C.Yusa K.Tsuruo T. J. Med. Chem. 1992, 35: 1882 - 6b
Tanaka M.Norimine Y.Fujita T.Suemune H. J. Org. Chem. 1996, 61: 6952 - 7
Wang J.Jin Y.Rapp KL.Bennett M.Schinazi RF.Chu CK. J. Med. Chem. 2005, 48: 3736 - 8
Wang J.Jin Y.Rapp KL.Schinazi RF.Chu CK. J. Med. Chem. 2007, 50: 1828 - 9
Huang W.Miller JM.De Clercq E.Balzarini J. Org. Biomol. Chem. 2007, 5: 1164 - 10
Sriram D.Yogeeswari P.Myneedu NS.Saraswat V. Bioorg. Med. Chem. Lett. 2006, 16: 2127 - 11
Brémond P.Audran G.Aubin Y.Monti H. Synlett 2007, 1124 - 12a
Trost BM.Li L.Guile SD. J. Am. Chem. Soc. 1992, 114: 8745 - 12b
Trost BM. J. Org. Chem. 2004, 69: 5813 - 13
Audran G.Acherar S.Monti H. Eur. J. Org. Chem. 2003, 5: 92 - 14
Saville-Stones EA.Lindell SD.Jennings NS.Head JC.Ford MI. J. Chem. Soc., Perkin Trans. 1 1991, 2603 - 15
Falck-Pedersen ML.Benneche T.Undheim K. Acta Chem. Scand. 1993, 47: 63 - 16a
Shealy YF.Clayton JD. J. Pharm. Sci. 1973, 62: 1432 - 16b
Taylor SJC.Sutherland AG.Lee C.Wisdow R.Thomas S.Roberts SM.Evans CT. J. Chem. Soc., Chem. Commun. 1990, 1120 - 16c
Evans CT.Roberts SM.Shoberu KA.Sutherland AG. J. Chem. Soc., Perkin Trans. 1 1992, 589 - 17
Thompson AS.Humphrey GR.DeMarco AM.Mathre DJ.Grabowski EJJ. J. Org. Chem. 1993, 58: 5886 - 18 It is a general observation that
the cis-1,4-disubstituted cyclopentenes
present differences in the range of 1 ppm in the chemical shifts
of their H-5 protons with the upfield proton assigned as syn to both substituents. Alternatively, the
difference does not usually exceed 0.3 ppm for the trans-isomer,
see:
Marino JP.Fernandez de la Pradilla R.Laborde E. J. Org. Chem. 1987, 52: 4893 ; and references cited therein - 19
Anti-HIV
Nucleosides: Past, Present and Future
Mitsuya H. R. G. Landes Co.; Georgetown TX: 1997. - 20a
Montgomery JA.Temple C. J. Am. Chem. Soc. 1957, 79: 5238 - 20b
Shealy YF.Clayton JD. J. Am. Chem. Soc. 1966, 88: 3885 - 20c
Shealy YF.Clayton JD. J. Am. Chem. Soc. 1969, 91: 3075 - 20d
Arita M.Adachi K.Ito Y.Sawai H.Ohno M. J. Am. Chem. Soc. 1983, 105: 4049 - 21
Pauwels R.Balzarini J.Baba M.Snoeck R.Schols D.Herdewijn P.Desmyter J.De Clercq E. J. Virol. Methods 1988, 20: 309 - 22
Popovic M.Sarngadharan MG.Read E.Gallo RC. Science 1984, 224: 497 - 23
Barrè-Sinoussi F.Chermann JC.Rey F.Nugeyre MT.Chamaret S.Grest J.Dauget C.Axler-Blin C.Vezinet-Brun F.Rouzioux C.Rozenbaum W.Montagnier L. Science 1983, 220: 868 - 24
Miyoshi I.Taguchi H.Kobonishi I.Yoshimoto S.Ohtsuki Y.Shiraishi Y.Akagi T. Gann Monogr. 1982, 28: 219 - 25
De Clercq E.Descamps J.Verhelst G.Walker RT.Jones AS.Torrence PF.Shugar D. J. Infect. Dis. 1980, 141: 563 - 26
De Clercq E. Antimicrob. Agents Chemother. 1985, 28: 84 - 27
De Clercq E.Holý A.Rosenberg I.Sakuma T.Balzarini J.Maudgal PC. Nature 1986, 323: 464